- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00534703
Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure (SERCA-LVAD)
Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure and a Left Ventricular Assist Device
Study Overview
Status
Intervention / Treatment
Detailed Description
It is a randomised, double-blind study of 24 patients that will be randomised to receive either the study drug (AAV1.SERCA2a) or placebo.
The purpose of gene transfer of SERCA2a is to improve systolic and diastolic function of the failing ventricle. Studies show that reduction of SERCA2a in failing ventricle is a key factor in depression of contraction, and that restoration of SERCA2a levels can improve function to near normal levels. The vector will be delivered during a cardiac catheterisation procedure by a 10-minute infusion into the coronary arteries.
Myocardial tissue is obtained at the time of LVAD placement, as a routine part of device implantation. Further samples will be obtained when the heart is transplanted or the LVAD removed. Measures of tissue inflammation as well as efficacy of gene transfer will be made by comparing these two samples. Recovery of contractile function of the heart will be assessed during attempts to wean patients from the LVAD using standard protocols.
The results will be assessed in conjunction with two companion studies which will start earlier in the US, one performing SERCA2a gene transfer with the same vector, but delivered by direct injection into the myocardium during LVAD insertion, and one using AAV1-CMV-SERCA2a delivered percutaneously in heart failure patients. The latter has both a dose-ranging and placebo-controlled arm.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Cambridge, United Kingdom, CB23 3RE
- Papworth Hospital
-
Middlesex, United Kingdom, UB9 6JH
- Harefield Hospital, Royal Brompton and Harefiled NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Patients that have had a left ventricular assist device (LVAD) implanted for chronic heart failure, where chronic heart failure is defined as at least 6 months
- Patients are clinically stable in the opinion of the clinical team looking after the patient
- Written informed consent
Exclusion criteria
- <18 or >70 years of age at the time of consent
- Pregnancy or within 6 months of giving birth
- Women of child-bearing potential not using an effective method of contraception
- Men not using an effective method of contraception
- Suspected or active viral, fungal or parasitic infection within 48 hours prior to administration of IMP, in the opinion of the investigator*.
- Patients at a high risk of thrombosis in the opinion of the investigator
- Patients with a previous episode of LVAD thrombosis
- Patients with persistently raised lactate dehydrogenase (LDH >2.5 ULN)
- Patients requiring triple anticoagulation i.e. warfarin and dual anti-platelet
- Patients participating in another clinical trial
Patients unable to comply with the protocol mandated procedures for social or other reasons, in the opinion of the investigator and primary care physician
- Eligible, enrolled and randomised patients who develop an infection will have study treatment delayed until 7 or more days after the time point when infection is no longer clinically evident.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: AAV1/SERCA2A
SERCA gene therapy
|
AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory.
Dose: 1x 10^13 DRP (DNase resistant particles)
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Placebo (saline solution)
|
Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product.
Placebo is prepared and handled exactly as above in a blinded fashion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Safety and Feasibility of Administering AAV1/SERCA2a to LVAD Patients
Time Frame: 6 months
|
Safety is defined as the incidence of patients experiencing death and major adverse cardiovascular events, and out of range laboratory values.
Both AAV1/SERCA2a treated cohorts (NAb+ and NAb-) will be compared to the placebo group.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Exogenous Viral Vector Genome in the Myocardium Measured by qPCR for the Viral DNA
Time Frame: 6 months
|
The trial was terminated early with only 5 subjects enrolled.
As a result full statistical analysis for both primary and secondary outcomes was impossible and a more pragmatic approach was undertaken to assess product safety.
|
6 months
|
Left Ventricular Function (LVEF)
Time Frame: 6 months
|
Left ventricular function assessed by echocardiography and exercise capacity (6MWT, MVO2) during minimal LVAD support (low/no flow settings depending upon device) LVEF expressed as %
|
6 months
|
Levels of SERCA2a Protein
Time Frame: 6 months
|
6 months
|
|
Other Relevant Proteins e.g. Phospholamban, the Sarcoplasmic Reticulum Calcium Release Channel, the Na+/Ca2+-Exchanger.
Time Frame: 6 months
|
6 months
|
|
Function of Isolated Myocytes
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRO782
- 2007-002809-48 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Heart Failure
-
Maastricht University Medical CenterUniversity College Dublin; RWTH Aachen University; Queen's University, BelfastCompletedChronic Heart FailureNetherlands, Germany, Ireland, United Kingdom
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Jordan Cardio Vascular Research GroupRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureJordan
-
Lithuanian University of Health SciencesCompletedHeart Failure | Chronic Heart Failure | Congestive Heart Failure | Right Ventricular FailureLithuania
-
Zensun Sci. & Tech. Co., Ltd.RecruitingChronic Heart FailureChina
-
University Hospital, Clermont-FerrandHospices Civils de Lyon; University Hospital, Grenoble; Hôpital de la Croix-Rousse and other collaboratorsRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureFrance
-
University of Roma La SapienzaUnknownChronic Heart Failure | Decompensated Heart Failure | Morality
-
University Medicine GreifswaldDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)RecruitingChronic Heart FailureGermany
-
University Hospital, Gentofte, CopenhagenUnknownChronic Heart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVDenmark
-
AquaPass Medical Ltd.CompletedChronic Heart FailureIsrael
Clinical Trials on AAV1/SERCA2a
-
Celladon CorporationCompletedHeart Failure | Cardiomyopathies | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathyUnited States, United Kingdom, Belgium, Germany, Poland, Israel, Netherlands, Hungary, Denmark, Sweden
-
Sardocor Corp.RecruitingHeart Failure, Diastolic | Heart Failure With Preserved Ejection FractionUnited States
-
Celladon CorporationTerminatedHeart Failure | Cardiomyopathies | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathyUnited States
-
Celladon CorporationCompletedDilated Cardiomyopathy | Heart Failure, CongestiveUnited States
-
GenethonCompletedLimb Girdle Muscular Dystrophy Type 2C | Gamma-sarcoglycanopathyFrance
-
Sardocor Corp.Not yet recruitingDMD-Associated Dilated Cardiomyopathy